Health Condition 1: I272- Other secondary pulmonary hypertension Health Condition 2: I278- Other specified pulmonary heart diseases Health Condition 3: I270- Primary pulmonary hypertension
Conditions
Interventions
Intervention1: Yoga based cardiac rehabilitation programme (Yoga-CaRe): Yoga based cardiac rehabilitation programme comprising of yogic practices such as asana, pranayama meditation and lifestyle prac
Sponsors
Central Council for Research in Yoga and Naturopathy
Eligibility
Inclusion criteria
Inclusion criteria: Patients with pulmonary hypertension, defined as peak tricuspid regurgitation velocity of more than 3.5meters per second by 2 dimensional echocardiogram. Stable on medications for 3 months prior to enrollment WHO functional class II and III 6MWD less than 440m
Exclusion criteria
Exclusion criteria: Patients who choose to get recruited in the cardiopulmonary rehabilitation program. WHO functional class 1 and 4. Recent episode of syncope within less than 1 month. Recent acute coronary event within less than 3 months Evidence of left heart failure. Pregnant or planning to get pregnant in the study period. Uncontrolled arrhythmia. Unstable angina. Practicing yoga regularly more or enrolled in cardiac rehabilitation program. Participating in any other clinical trial Significant neuromuscular complications inhibiting participation in the trial. Significant hepatic or renal dysfunction Enzymes more than 2 times normal or Serum creatinine more than 2 times.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The six-minute walk distance obtained from the six-minute walk testTimepoint: At baseline, three months and six months | — |
Secondary
| Measure | Time frame |
|---|---|
| WHO functional classTimepoint: Baseline, three months and six months;Quality of life assessment using emPHasis 10 questionnaireTimepoint: baseline, three months and six months;Cardiopulmonary exercise testTimepoint: Baseline and six months;EchocardiogramTimepoint: At baseline, three months and six months;N terminal pro brain natriuretic peptideTimepoint: Baseline and six months;Interleukin 6Timepoint: At baseline and six months;high sensitivity CRPTimepoint: At baseline and six months;Heartrate variabilityTimepoint: At baseline and six months | — |
Countries
India
Contacts
Public ContactDr Ambalam M Chandrasekaran
Centre for Chronic Disease Control, Department of Clinical Trials,
Outcome results
None listed